Arrayit Corporation (ARYC) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Arrayit Corporation (ARYC) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Die Aktie erzielt 58/100, eine moderate Bewertung basierend auf 9 quantitativen KPIs.
Zuletzt analysiert: 16. März 2026Arrayit Corporation (ARYC) Gesundheitswesen & Pipeline-Uebersicht
Arrayit Corporation develops, manufactures, and markets life science tools and integrated systems for genetic variation analysis and diagnostics. The company's microarray technology and instruments serve genomic research centers, pharmaceutical companies, and academic institutions. With a focus on early disease detection, Arrayit operates in the competitive medical diagnostics and research sector.
Investmentthese
Arrayit Corporation operates in the medical diagnostics and research sector, focusing on microarray technology. The company's gross margin of 49.4% indicates potential profitability in its core operations. However, the negative profit margin of -231.4% raises concerns about overall financial health. Key growth catalysts include expanding the application of its microarray technology in early disease detection and increasing sales of automated microarray instruments. Potential risks include the company's small market capitalization of $0.00B and high beta of -15.67, indicating high volatility. Investors should carefully consider the financial metrics and market position before investing.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Gross margin of 49.4% suggests potential efficiency in Arrayit's core microarray technology business.
- Negative profit margin of -231.4% raises concerns about the company's overall financial health and expense management.
- Market capitalization of $0.00B indicates the company is a micro-cap stock with associated volatility and liquidity risks.
- Beta of -15.67 suggests the stock price moves inversely and with greater magnitude than the market, indicating high volatility.
- Arrayit serves genomic research centers, pharmaceutical companies, and academic institutions, indicating a diversified customer base within the life sciences sector.
Staerken
- Proprietary microarray printing technology
- Integrated systems for genetic variation analysis
- Established relationships with research institutions
- Specialized expertise in microarray applications
Schwaechen
- Negative profit margin
- Small market capitalization
- High beta indicating high volatility
- Limited financial resources
Katalysatoren
- Ongoing: Expansion of microarray applications in early disease detection.
- Ongoing: Increasing sales of automated microarray instruments.
- Ongoing: Development and marketing of consumables for microarray technology.
- Ongoing: Entering strategic partnerships with pharmaceutical companies.
- Ongoing: Expanding into international markets.
Risiken
- Potential: Competition from larger companies with greater resources.
- Potential: Regulatory changes affecting the medical diagnostics industry.
- Potential: Technological advancements rendering current products obsolete.
- Potential: Economic downturns impacting research funding.
- Ongoing: Negative profit margin and limited financial resources.
Wachstumschancen
- Expanding Microarray Applications in Early Disease Detection: Arrayit can capitalize on the growing demand for early disease detection by developing and marketing diagnostic microarrays for various treatable disease states. The market for early disease diagnostics is projected to reach billions of dollars by 2030, driven by advancements in genomics and proteomics. Arrayit's microarray technology offers a platform for high-throughput screening and personalized medicine, providing a competitive advantage in this expanding market. Timeline: Ongoing.
- Increasing Sales of Automated Microarray Instruments: Arrayit can increase revenue by expanding the sales of its automated microarray manufacturing instruments, such as NanoPrint and SpotBot Titan, to research institutions and pharmaceutical companies. The market for automated laboratory equipment is expected to grow, driven by the need for increased efficiency and throughput in research and development. Arrayit's instruments offer customizable solutions for microarray manufacturing, catering to the specific needs of its customers. Timeline: Ongoing.
- Developing and Marketing Consumables for Microarray Technology: Arrayit can leverage its existing customer base by developing and marketing consumables, such as glass substrates, reagents, and clean room supplies, for microarray technology. The market for laboratory consumables is stable and recurring, providing a consistent revenue stream for the company. By offering high-quality consumables specifically designed for its instruments, Arrayit can enhance customer loyalty and increase market share. Timeline: Ongoing.
- Entering Strategic Partnerships with Pharmaceutical Companies: Arrayit can accelerate its growth by entering strategic partnerships with pharmaceutical companies to develop and commercialize diagnostic microarrays and tools for specific disease areas. Collaborating with established pharmaceutical companies can provide access to funding, expertise, and distribution channels, enabling Arrayit to expand its market reach and product portfolio. These partnerships can focus on developing personalized medicine solutions and companion diagnostics. Timeline: Ongoing.
- Expanding into International Markets: Arrayit can expand its geographic reach by targeting international markets, particularly in Asia and Europe, where there is growing demand for life science tools and diagnostic technologies. Entering new markets requires adapting products and services to local regulatory requirements and customer needs. By establishing partnerships with local distributors and research institutions, Arrayit can effectively penetrate these markets and increase its global presence. Timeline: Ongoing.
Chancen
- Expanding microarray applications in early disease detection
- Increasing sales of automated microarray instruments
- Developing and marketing consumables
- Entering strategic partnerships with pharmaceutical companies
Risiken
- Competition from larger companies
- Regulatory changes
- Technological advancements
- Economic downturns
Wettbewerbsvorteile
- Proprietary microarray printing technology.
- Integrated systems for genetic variation analysis.
- Established relationships with research institutions and pharmaceutical companies.
- Specialized expertise in microarray technology and applications.
Ueber ARYC
Arrayit Corporation, founded to advance life science research and diagnostics, develops, manufactures, and markets tools and integrated systems for analyzing genetic variation and biological function. The company's core business revolves around microarray technology, which enables the analysis of DNA, protein, antibody, lipid, and carbohydrate microarrays for applications such as gene expression, genotyping, and protein profiling. Arrayit offers a range of automated microarray manufacturing instruments, including the NanoPrint, SpotBot Titan, and SpotLight CCD fluorescence scanners. These instruments cater to various research and diagnostic needs, providing solutions for high-throughput sample processing and analysis. In addition to instruments, Arrayit manufactures consumables like glass substrates, reagents, and clean room supplies. The company serves genomic research centers, pharmaceutical companies, academic institutions, clinical research organizations, government agencies, and biotechnology companies worldwide. Headquartered in Sunnyvale, California, Arrayit Corporation continues to focus on developing innovative tools for early disease detection and advancing life science research.
Was das Unternehmen tut
- Develops microarray tools and components.
- Manufactures life science tools and integrated systems.
- Markets life science tools and integrated systems.
- Offers custom printing and analysis of microarrays for research.
- Identifies and develops diagnostic microarrays for early disease detection.
- Provides automated microarray manufacturing instruments.
Geschaeftsmodell
- Sales of microarray tools and components to research institutions and pharmaceutical companies.
- Custom printing and analysis of microarrays for research purposes.
- Development and sales of diagnostic microarrays for early disease detection.
- Manufacturing and sales of automated microarray manufacturing instruments.
Branchenkontext
Arrayit Corporation operates within the medical diagnostics and research industry, a sector characterized by rapid technological advancements and increasing demand for personalized medicine. The market for microarray technology is driven by the need for high-throughput analysis of genetic variation and biological function. Arrayit competes with companies offering similar tools and services, including those specializing in genomics, proteomics, and diagnostics. The industry is subject to regulatory requirements and intellectual property protection, influencing the competitive landscape and market access.
Wichtige Kunden
- Genomic research centers
- Pharmaceutical companies
- Academic institutions
- Clinical research organizations
- Government agencies
- Biotechnology companies
Finanzdaten
Chart & Info
Arrayit Corporation (ARYC) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Stocks That Hit 52-Week Lows On Tuesday
· 24. März 2020
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer ARYC.
Kursziele
Wall-Street-Kurszielanalyse fuer ARYC.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von ARYC auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Rene A. Schena
Managing
Rene A. Schena is the managing person at Arrayit Corporation, overseeing the company's operations and strategic direction. Information about his detailed career history, education, and previous roles is not available in the provided data. He is responsible for leading the company's efforts in developing, manufacturing, and marketing life science tools and integrated systems.
Erfolgsbilanz: Due to limited information, Rene A. Schena's specific achievements, strategic decisions, and company milestones under his leadership cannot be comprehensively assessed. However, as the managing person, he is responsible for guiding the company's activities in the competitive life sciences technology sector and managing its seven employees.
ARYC OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Arrayit Corporation may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in OTC Other stocks carries higher risks compared to stocks listed on major exchanges like NYSE or NASDAQ due to the lack of stringent listing requirements and regulatory oversight.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for price manipulation
- Higher risk of fraud or mismanagement
- Lack of regulatory oversight
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Check for any legal or regulatory issues.
- Monitor news and press releases for any updates or developments.
- Consult with a financial advisor before investing.
- Development of microarray tools and components.
- Manufacturing of life science tools and integrated systems.
- Marketing of life science tools and integrated systems.
Was Anleger ueber Arrayit Corporation (ARYC) wissen wollen
What are the key factors to evaluate for ARYC?
Arrayit Corporation (ARYC) currently holds an AI score of 58/100, indicating moderate score. Key strength: Proprietary microarray printing technology. Primary risk to monitor: Potential: Competition from larger companies with greater resources.. This is not financial advice.
How frequently does ARYC data refresh on this page?
ARYC prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ARYC's recent stock price performance?
Recent price movement in Arrayit Corporation (ARYC) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary microarray printing technology. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ARYC overvalued or undervalued right now?
Determining whether Arrayit Corporation (ARYC) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ARYC?
Before investing in Arrayit Corporation (ARYC), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ARYC to a portfolio?
Potential reasons to consider Arrayit Corporation (ARYC) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Proprietary microarray printing technology. Additionally: Integrated systems for genetic variation analysis. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of ARYC?
Yes, most major brokerages offer fractional shares of Arrayit Corporation (ARYC) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ARYC's earnings and financial reports?
Arrayit Corporation (ARYC) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for ARYC earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available company data and may be limited due to OTC listing.
- AI analysis pending for ARYC.